Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Scherr, D; Turagam, MK; Maury, P; Blaauw, Y; van, der, Voort, P; Neuzil, P; Reichlin, T; Metzner, A; Vijgen, J; Kautzner, J; Boveda, S; Anic, A; Hansen, J; Manninger, M; Sommer, P; Anselme, F; Willems, S; Deneke, T; Tilz, R; Steven, D; Wakili, R; Jais, P; Funasako, M; Arentz, T; Rollin, A; Mulder, BA; Ouss, A; Petru, J; Kueffer, T; Lemoine, MD; Koopman, P; Peichl, P; Adelino, R; Jurisic, Z; Ruwald, M; Eberl, AS; Sohns, C; Savoure, A; Nentwich, K; Gunawardene, M; Heeger, CH; Sultan, A; Bohnen, JE; Kupusovic, J; Derval, N; Lehrmann, H; Ekanem, E; Reddy, VY.
Repeat procedures after pulsed field ablation for atrial fibrillation: MANIFEST-REDO study.
Europace. 2025; 27(8): Doi: 10.1093/europace/euaf012 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Scherr Daniel
Co-authors Med Uni Graz: Eberl Anna-Sophie; Manninger-Wünscher Martin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: AIMS: Initial clinical studies of pulsed field ablation (PFA) to treat atrial fibrillation (AF) indicated a >90% durability rate of pulmonary vein isolation (PVI). However, these studies were largely conducted in single centres and involved a limited number of operators. We aimed to describe the electrophysiological findings and outcomes in patients undergoing repeat ablation after an initial PF ablation for AF. METHODS AND RESULTS: In the MANIFEST-REDO study, we investigated patients who underwent repeat ablation due to clinical recurrence-AF or atrial tachycardia (AT)-following first-ever PVI with a pentaspline PFA catheter (Farawave, Boston Scientific Inc.). At 22 centres, 427 patients (age 64 ± 11 years; 37% female) were included. Of note, the recurrent arrhythmia leading to the repeat ablation was paroxysmal AF (51%), persistent AF (30%), or AT (19%). At the repeat procedure, the PV reconnection rates were 30% (left superior pulmonary vein), 28% (left inferior pulmonary vein), 33% (right superior pulmonary vein), and 32% (right inferior pulmonary vein). In 45% of patients, all PVs were durably isolated at the beginning of the repeat procedure, with the previous use of any imaging or mapping modality being univariately associated with durable PVI. After a post-redo follow-up period of 284 (90-366) days, the primary effectiveness endpoint (freedom from documented AF/AT lasting ≥30 s after 3-month blanking without class I/III antiarrhythmic drugs or symptoms) was achieved in 65% of patients, with significant differences between groups (PAF 65% vs. PersAF 56% vs. AT 76%; P = 0.04). Persistent AF as recurrent arrhythmia after the initial PFA ablation predicted AT/AF recurrence after repeat ablation [hazard ratio 1.241 (95% confidence interval 1.534-1.005); P = 0.045]. The procedural complication rate was 2.8%. CONCLUSION: In repeat procedures for AF/AT performed after an index procedure with PFA for AF, PV reconnections are not uncommon. Repeat procedures can be performed safely and with an acceptable subsequent success rate.
Find related publications in this database (Keywords): Atrial fibrillation; Atrial tachycardia; Electroporation; Pulsed field ablation; Pulmonary vein isolation